Dixon Debra D, Knapp Shannon M, Ilonze Onyedika, Lewsey Sabra C, Mazimba Sula, Mohammed Selma, Van Spall Harriette G C, Breathett Khadijah
Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Division of Cardiovascular Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
JACC Heart Fail. 2023 Oct;11(10):1397-1407. doi: 10.1016/j.jchf.2023.05.017. Epub 2023 Jun 28.
Durable left ventricular assist devices (VADs) improve survival in eligible patients, but allocation has been associated with patient race in addition to presumed heart failure (HF) severity.
This study sought to determine racial and ethnic differences in VAD implantation rates and post-VAD survival among patients with ambulatory HF.
Using the INTERMACS (Interagency Registry of Mechanically Assisted Circulatory Support) database (2012-2017), this study examined census-adjusted VAD implantation rates by race, ethnicity, and sex in patients with ambulatory HF (INTERMACS profile 4-7) using negative binomial models with quadratic effect of time. Survival was evaluated using Kaplan-Meier estimates and Cox models adjusted for clinically relevant variables and an interaction of time with race/ethnicity.
VADs were implanted in 2,256 adult patients with ambulatory HF (78.3% White, 16.4% Black, and 5.3% Hispanic). The median age at implantation was lowest in Black patients. Implantation rates peaked between 2013 and 2015 before declining in all demographic groups. From 2012 to 2017, implantation rates overlapped for Black and White patients but were lower for Hispanic patients. Post-VAD survival was significantly different among the 3 groups (log rank P = 0.0067), with higher estimated survival among Black vs White patients (12-month survival: Black patients: 90% [95% CI: 86%-93%]; White patients: 82% [95% CI: 80%-84%]). Low sample size for Hispanic patients resulted in imprecise survival estimates (12-month survival: 85% [95% CI: 76%-90%]).
Black and White patients with ambulatory HF had similar VAD implantation rates but rates were lower for Hispanic patients. Survival differed among the 3 groups, with the highest estimated survival at 12 months in Black patients. Given higher HF burden in minoritized populations, further investigation is needed to understand differences in VAD implantation rates in Black and Hispanic patients.
耐用的左心室辅助装置(VAD)可提高符合条件患者的生存率,但除了假定的心力衰竭(HF)严重程度外,分配还与患者种族有关。
本研究旨在确定门诊HF患者中VAD植入率和VAD植入后生存率的种族和民族差异。
本研究使用INTERMACS(机械辅助循环支持机构间注册中心)数据库(2012 - 2017年),采用具有时间二次效应的负二项式模型,按种族、民族和性别对门诊HF患者(INTERMACS概况4 - 7)的人口普查调整后VAD植入率进行了研究。使用Kaplan - Meier估计值和针对临床相关变量以及时间与种族/民族相互作用进行调整的Cox模型评估生存率。
2256例成年门诊HF患者接受了VAD植入(78.3%为白人,16.4%为黑人,5.3%为西班牙裔)。黑人患者植入时的年龄中位数最低。植入率在2013年至2015年达到峰值,之后在所有人口统计学组中均下降。2012年至2017年,黑人和白人患者的植入率有重叠,但西班牙裔患者的植入率较低。三组患者VAD植入后的生存率有显著差异(对数秩检验P = 0.0067),黑人患者的估计生存率高于白人患者(12个月生存率:黑人患者:90%[95%CI:86% - 93%];白人患者:82%[95%CI:80% - 84%])。西班牙裔患者样本量小导致生存率估计不准确(12个月生存率:85%[95%CI:76% - 90%])。
门诊HF的黑人和白人患者VAD植入率相似,但西班牙裔患者的植入率较低。三组患者的生存率不同,黑人患者12个月时的估计生存率最高。鉴于少数族裔人群的HF负担较重,需要进一步研究以了解黑人和西班牙裔患者VAD植入率的差异。